13,211 Shares in Gilead Sciences, Inc. $GILD Acquired by SBI Okasan Asset Management Co.Ltd.

Key Points

• SBI Okasan Asset Management disclosed a new fourth-quarter position in Gilead Sciences, buying 13,211 shares valued at about $1.65 million.
• Gilead’s latest quarterly results beat expectations, with EPS of $2.03 versus $1.91 expected and revenue of $6.96 billion, up 4.4% year over year.
• The company also announced a quarterly dividend of $0.82 per share and has drawn mostly bullish analyst sentiment, with an average rating of Moderate Buy and an average price target of $156.93.

SBI Okasan Asset Management Co.Ltd. acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 13,211 shares of the biopharmaceutical company's stock, valued at approximately $1,650,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Ares Financial Consulting LLC acquired a new position in Gilead Sciences in the 4th quarter worth approximately $28,000. Financial Consulate Inc. boosted its stake in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 109 shares during the period. North Star Investment Management Corp. boosted its stake in Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 86 shares during the period. MTM Investment Management LLC boosted its stake in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 176 shares during the period. Finally, BOCHK Asset Management Ltd acquired a new position in Gilead Sciences in the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a "buy" rating in a research note on Wednesday, February 11th. Royal Bank Of Canada decreased their price objective on shares of Gilead Sciences from $123.00 to $122.00 and set a "sector perform" rating for the company in a research note on Friday, May 8th. Jefferies Financial Group began coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They set a "buy" rating and a $180.00 target price for the company. Truist Financial reissued a "buy" rating and set a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Finally, Argus lifted their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a "buy" rating in a research note on Thursday, February 19th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average price target of $156.93.

Gilead Sciences Trading Up 1.9%

Shares of NASDAQ:GILD opened at $136.22 on Friday. The firm has a market capitalization of $169.13 billion, a P/E ratio of 18.56 and a beta of 0.31. The firm has a fifty day moving average of $135.43 and a two-hundred day moving average of $134.08. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12-month low of $104.46 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences's revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences's dividend payout ratio (DPR) is currently 44.69%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. This represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 53,000 shares of company stock worth $7,075,670. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.